Tadalafil, a phosphodiesterase inhibitor protects stem cells over longer period against hypoxia/reoxygenation injury through STAT3/PKG-I signaling

Stem Cells and Development

Volumn 24, Issue 11, 2015, Pages 1332-1341

  Kumar, Sanjay ^a   Ashraf, Muhammad ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; OXYGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN; TADALAFIL; TRYPAN BLUE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; PHOSPHODIESTERASE INHIBITOR; STAT3 PROTEIN, RAT;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL HYPOXIA; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME RELEASE; IN VITRO STUDY; ISCHEMIC PRECONDITIONING; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REOXYGENATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STAINING; TUNEL ASSAY; ANIMAL; DRUG EFFECTS; FISCHER 344 RAT; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM;

RATTUS;

ANIMALS; CELL HYPOXIA; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; MALE; MESENCHYMAL STROMAL CELLS; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; PHOSPHODIESTERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TADALAFIL;

EID: 84929581820     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0288     Document Type: Article

References (37)

1. Fliss H and D Gattinger. (1996). Apoptosis in ischemic and reperfused rat myocardium. Circ Res 79:949-956.
2. Takimoto E, HC Champion, M Li, D Belardi, S Ren, ER Rodriguez, D Bedja, KL Gabrielson, Y Wang and DA Kass. (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222.
3. Rybalkin SD, C Yan, KE Bornfeldt and JA Beavo. (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Cir Res 93:280-291.
4. Reffelmann T and RA Kloner. (2003). Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239-244.
5. Takimoto E, HC Champion, D Belardi, J Moslehi, M Mongillo, E Mergia, DC Montrose, T Isoda, K Aufiero, et al. (2005). Cyclic GMP catabolism by PDE5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96:100-109.
6. Sesti C, V Florio, EG Johnson and RA Kloner. (2007). The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 19:55-61.
7. Hofmann F. (2005). The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280:1-4.
8. Hofmann F, A Ammendola and J Schlossmann. (2000). Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113:1671-1676.
9. Bolli R. (2000). The late phase of preconditioning. Circ Res 87:972-983.
10. Guo Y, WK Jones, YT Xuan, XL Tang, W Bao, WJ Wu, H Han, VE Laubach, P Ping, et al. (1999). The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96:11507-11512.
11. Ping P, J Zhang, Y Qiu, XL Tang, S Manchikalapudi, X Cao and R Bolli. (1997). Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 81:404-414.
12. Ping P, J Zhang, YT Zheng, RC Li, B Dawn, XL Tang, H Takano, Z Balafanova and R Bolli. (1999). Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ Res 85:542-550.
13. Xuan YT, XL Tang, S Banerjee, H Takano, RC Li, H Han, Y Qiu, JJ Li and R Bolli. (1999). Nuclear factorkappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84: 1095-1109.
14. Das A, A Smolenski, SM Lohmann and RC Kukreja. (2006). Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem 281: 38644-38652.
15. Das A, R Ockaili, F Salloum and RC Kukreja. (2003). Protein kinase C plays an essential role in sildenafilinduced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286:H1455-H1460.
16. Salloum F, C Yin, L Xi and RC Kukreja. (2003). Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597.
17. Das A, L Xi and RC Kukreja. (2008). Protein kinase Gdependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
18. Darnell JE Jr. (1999). STATs and gene regulation. Science 277:1630-1635.
19. Heim MH. (1999). The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 19:75-120.
20. Negoro S, K Kunisada, E Tone, M Funamoto, H Oh, T Kishimoto and K Yamauchi-Takihara. (2000). Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47:797-805.
21. Haider HKh, YJ Lee, S Jiang, RP Ahmed, M Ryon and M Ashraf. (2010). Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells. Am J Physiol Heart Circ Physiol 299:H1395-H1404.
22. Foresta C, A Lana, A Cabrelle, M Ferigo, N Caretta, A Garolla, G Palù and A Ferlin. (2005). PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 17:377-380
23. Florea V, SS Majid, RM Kanashiro-Takeuchi, RZ Cai, NL Block, AV Schally, JM Hare and CO Rodrigues. (2014). Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc Natl Acad Sci U S A. 111:17260-17265.
24. Wang L, Z Pasha, S Wang, N Li, Y Feng, G Lu, RW Millard and M Ashraf. (2013). Protein kinase G1 a overexpression increases stem cell survival and cardiac function after myocardial infarction. PLoS One 8:e60087.
25. Rakhit RD, RJ Edwards, JW Mockridge, AR Baydoun, AW Wyatt, GE Mann and MS Marber. (2000). Nitric oxide-induced cardioprotection in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 278:H1211-H1217.
26. Hodgetts SI, MW Beilharz, AA Scalzo and MD Grounds. (2000). Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4 + and CD8 + cells or Nk1.1 + cells. Cell Transplant 9:489-502.
27. Rybalkin SD, IG Rybalkina, M Shimizu-Albergine, XB Tang and JA Beavo. (2003). PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469-478.
28. Garlid KD, AD Costa, CL Quinlan, SV Pierre and Dos Santos P. (2009). Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 46:858-866.
29. Tong H, W Chen, C Steenbergen and E Murphy. (1999). Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87:309-315.
30. Datta SR, A Brunet and ME Greenberg. (1999). Cellular survival: a play in three Akts. Genes Dev 13:2905-2927.
31. Dimmeler S, I Fleming, B Fisslthaler, C Hermann, R Busse and AM Zeiher. (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605.
32. Matsui T, J Tao, F del Monte, KH Lee, L Li, M Picard, TL Force, TF Franke, RJ Hajjar and A Rosenzweig. (2001). Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104:330-335.
33. Weston CR, K Balmanno, C Chalmers, K Hadfield, SA Molton, R Ley, EF Wagner and SJ Cook. (2003). Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22:1281-1293.
34. Cardone MH, N Roy, HR Stennicke, GS Salvesen, TF Franke, E Stanbridge, S Frisch and JC Reed. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
35. Nishihara M, T Miura, T Miki, M Tanno, T Yano, K Naitoh, K Ohori, H Hotta, Y Terashima and K Shimamoto. (2007). Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43:564-570.
36. Xuan YT, G Yiru, H Hui, Z Yanqing and R Bolli. (2001). An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A 98:9050-9055.
37. Xie Q, Y Kashiwabara and C Nathan. (1994). Role of transcription factor NF-ΠB/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705-4708.